Work

Imatinib Mesylate Is a Potent Inhibitor of the ABCG2 (BCRP) Transporter and Reverses Resistance to Topotecan and SN-38 in Vitro

Year: 2004

Type: article

Source: Cancer Research

DOI: 10.1158/0008-5472.can-03-3344

Authors: Peter J. Houghton, Glen S. Germain, Franklin C. Harwood, John D. Schuetz, Clinton F. Stewart, Elisabeth Buchdunger, Peter Traxler

Institutions: St. Jude Children's Research Hospital, Novartis (Switzerland)

Language: English

Topic: Drug Transport and Resistance Mechanisms

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: National Cancer Institute

Awards: G1139922818, MTOR as a Therapeutic Target in Childhood Cancer, G2499473270, Studies of Childhood Solid Tumors, G609259107, G707951704, Cancer Center Support Grant (CCSG)

OpenAlex ID: W1984246155

FWCI: 12.14

Cites: 11

Cited by: 322

Related to: 10